Activin and Inhibin

JH-XVI-178 is a highly potent and selective inhibitor of CDK8/19 that displays low clearance and moderate oral pharmacokinetic properties.Form:SolidIC50&amp: Target:CDK8 1 nM (IC 50 ) CDK19 2 nM (IC 50 ).

JHDM-IN-1 (Compound 1) is a Jumonji C domain-containing HDMs ( JHDM ) inhibitor with IC 50 s of 3.4, 4.3, 5.9, 10 and 43 μM against JMJD2C, JMJD2A, JMJD2E, PHF8 and JMJD3, respectivelyIn VitroJHDM-IN-1 (Compound 1) also inhibits FIH, PHD3, PHD1,

JKE-1674 is an orally active glutathione peroxidase 4 ( GPX4 ) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into

JKE-1674 is an orally active glutathione peroxidase 4 ( GPX4 ) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into

JKE-1674 is an orally active glutathione peroxidase 4 ( GPX4 ) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into

JKE-1674 is an orally active glutathione peroxidase 4 ( GPX4 ) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into

JKE-1716 is a potent and selective nitrolic acid-containing GPX4 inhibitor. JKE-1716 is able of inducing ferroptosis selectively through covalent GPX4 inhibitionIn VitroJKE-1716 (0~100 nΜ: 72 hours: LOX-IMVI cells) inhibits cell viability. JKE-1716

JKE-1716 is a potent and selective nitrolic acid-containing GPX4 inhibitor. JKE-1716 is able of inducing ferroptosis selectively through covalent GPX4 inhibitionIn VitroJKE-1716 (0~100 nΜ: 72 hours: LOX-IMVI cells) inhibits cell viability. JKE-1716

JMS-053 is a potent, selective and reversible PTP4A inhibitor, with IC 50 s of 29.1 nM, 48.0 nM, 34.7 nM, 92.6 nM, and 207.6 nM for PTP4A1 , PTP4A2 , PTP4A3 , CDC25B , and DUSP3 , respectively. JMS-053 can inhibit cancer cell migration and spheroid

JMS-053 is a potent, selective and reversible PTP4A inhibitor, with IC 50 s of 29.1 nM, 48.0 nM, 34.7 nM, 92.6 nM, and 207.6 nM for PTP4A1 , PTP4A2 , PTP4A3 , CDC25B , and DUSP3 , respectively. JMS-053 can inhibit cancer cell migration and spheroid

JMS-053 is a potent, selective and reversible PTP4A inhibitor, with IC 50 s of 29.1 nM, 48.0 nM, 34.7 nM, 92.6 nM, and 207.6 nM for PTP4A1 , PTP4A2 , PTP4A3 , CDC25B , and DUSP3 , respectively. JMS-053 can inhibit cancer cell migration and spheroid

JMV 449 acetate is a potent neurotensin receptor agonist. JMV 449 acetate shows an IC 50 of 0.15 nM for inhibition of 125 I-neurotensin binding to neonatal mouse brain and an EC 50 of 1.9 nM in contracting the guinea-pig ileum. JMV 449 acetate has